Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 11; no. 2; p. 174
Main Authors Fabian, Denise, Guillermo Prieto Eibl, Maria Del Pilar, Alnahhas, Iyad, Sebastian, Nikhil, Giglio, Pierre, Puduvalli, Vinay, Gonzalez, Javier, Palmer, Joshua D
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 02.02.2019
MDPI
Subjects
Brain cancer
Brain tumors
Cancer therapies
Chemotherapy
Clinical trials
Compliance
FDA approval
GBM
Glioblastoma
Oncology
Patients
Radiation therapy
Review
Temozolomide
TTF
tumor treating fields
United States > US
tumor treating fields
GBM
glioblastoma
TTF
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11020174